Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety, Immunogenicity and Efficacy Phase 1/2a Study of a Heterologous Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Regimen Plus Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults on Suppressive ART

NCT04983030 is registered in ClinicalTrials.gov with Boris Juelg, MD PhD as lead sponsor.

NCT NCT04983030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04983030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety, Immunogenicity and Efficacy Phase 1/2a Study of a Heterologous Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Regimen Plus Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults on Suppressive ART
Lead sponsor
Boris Juelg, MD PhD
Phase
Phase 1/2
Overall status
Completed
Start date
April 1, 2022
Completion date
February 23, 2026
Enrollment
28 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acquired immunodeficiency syndrome, hiv, immunologic deficiency syndrome, acquired, retroviridae infections, sexually transmitted diseases, viral